Core Viewpoint - The company, Shiyao Group, is expected to report a significant net loss for its subsidiary, Shiyao Innovation, in 2025, contrasting with a profit in the previous year, primarily due to increased R&D investments and operational challenges [1][2]. Group 1: Financial Performance - Shiyao Innovation anticipates a net loss attributable to shareholders of 170 million to 255 million yuan for 2025, compared to a profit of 53.7263 million yuan in the previous year [1]. - The expected net loss, excluding non-recurring items, is projected to be between 210 million and 315 million yuan, down from a profit of 42.3419 million yuan in the prior year [1]. Group 2: R&D Investments - The company is significantly increasing its R&D expenditures, with total R&D costs expected to rise to approximately 1 billion yuan, marking a substantial year-on-year increase [1]. - Several products in the pipeline have made important progress, including four antibody drugs, six ADC products, and one mRNA vaccine receiving clinical trial approvals for the first time in 2025 [1]. Group 3: Subsidiary Developments - In early November 2025, Shiyao Innovation completed the acquisition of an additional 29% minority stake in its subsidiary, Jushi Biotech, raising its ownership to 80% [2]. - The increased stake in Jushi Biotech, which is currently not profitable due to high R&D investments, will have a more pronounced impact on the consolidated financial statements of Shiyao Innovation [2]. Group 4: Functional Raw Materials Business - Shiyao Innovation is working to strengthen its position in the functional raw materials sector, particularly in caffeine products, although the gross margin and profitability of these products have slightly declined compared to the previous year due to market factors [2].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準 確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產 生或因倚賴該等內容而引致之任何損失承擔任何責任。 CSPC PHARMACEUTICAL GROUP LIMITED 石 藥 集 團 有 限 公 司 （股份代號：1093） （於香港註冊成立之有限公司） 石藥創新製藥股份有限公司 截至2025年12月31日止年度之業績預告 按深圳證券交易所之相關規定，石藥集團有限公司（「本公司」）之附屬公司石藥創新製藥股份 有限公司（「石藥創新」，其股份於深圳證券交易所創業板市場上市（ 股票代碼：300765）），已 於2026年1月15日發佈其截至2025年12月31日止年度之業績預告公告（「業績預告公告」）於深 圳證券交易所網站資訊披露頁面http:// www.szse.cn/ disclosure/listed/ notice/index.html。 本公司及董事會全體成員保證信息披露的內容真實、準確、完整，沒有虛假記載、誤導 性陳述或重大遺漏。 本公告附錄（「附錄」）所載由石藥創新根據中國企業會計準則編製之業 ...

Core Insights - Small nucleic acid drugs are emerging as potential leaders in the weight loss sector, shifting from merely "suppressing appetite" to "precisely regulating fat metabolism" [1][2] - The global weight loss market still has unmet needs despite the rapid uptake of GLP-1 drugs, which face issues such as rebound weight gain and gastrointestinal intolerance [2] - Domestic companies are quickly establishing small nucleic acid weight loss pipelines, focusing on targets, delivery platforms, and indications to unlock potential value in health weight loss and fatty liver disease [1][2] Group 1: INHBE Insights - INHBE, which encodes activin E, interacts with the ALK7 receptor in adipose tissue to inhibit fat breakdown, presenting a differentiated clinical value with strong drug development certainty [3] - Early clinical data for INHBE siRNA shows safety and efficacy in long-term fat loss while preserving muscle mass, with combined therapy yielding doubled weight loss and tripled visceral fat reduction compared to GLP-1 [3] - The GalNAc delivery system used for INHBE siRNA has proven clinical development certainty due to existing successful drugs like inclisiran [3] Group 2: ALK7 Insights - ALK7 siRNA requires a targeted delivery system to adipose tissue, with early clinical data indicating significant mRNA knockdown efficiency and sustained effects [4] - ARO-ALK7 demonstrated superior reduction in visceral fat compared to INHBE, with a 14.1% reduction observed at the 8-week mark after a single 200 mg dose [4] - The breakthrough in fat-targeted delivery systems is crucial for the competitive landscape of small nucleic acid drugs [4] Group 3: Investment Recommendations - Relevant investment targets include companies such as Heng Rui Medicine, Innovent Biologics, and others involved in small nucleic acid drugs [5] - The potential for small nucleic acid drugs in the weight loss market is significant, with various companies positioned to capitalize on this emerging trend [5]

Core Insights - The Chinese innovative drug industry is entering a new prosperous era characterized by significant BD transactions and a focus on source innovation [1][10] - This revival not only leads to valuation recovery for innovative drug companies but also reshapes the entire innovative drug industry chain [1][10] - The CXO industry and internet distribution platforms are expected to benefit from this growth cycle, emerging as "invisible winners" in the innovative drug boom [1][10] CXO Industry - WuXi AppTec, as a leader in the CXO industry, possesses a unique logic of beta and alpha resonance during this innovative drug prosperity cycle [2][11] - WuXi AppTec is projected to achieve approximately 45.456 billion yuan in revenue for 2025, a year-on-year increase of about 15.84%, with adjusted net profit expected to reach approximately 14.957 billion yuan, up 41.33% [3][12] - The company's growth is attributed to its integrated CRDMO (Contract Research, Development, and Manufacturing) business model, which significantly reduces R&D costs and complexity [3][12] Innovative Drug Commercialization - The number and quality of innovative drugs approved in China are experiencing explosive growth, with 76 innovative drugs approved in 2025, a 58.3% increase from 48 in 2024 [5][15] - New commercial channels, particularly internet platforms like JD Health and Alibaba Health, are emerging as core strategic channels for innovative drug commercialization [5][15] - JD Health has established itself as the "first station for new specialty drugs," allowing innovative drugs to be launched online immediately after approval, enhancing accessibility for patients [5][15][16] Investment Opportunities - The industry’s growth is expanding from solely innovative drug R&D companies to the entire supply chain, creating significant investment opportunities [17] - Index theme funds are suggested as a means for ordinary investors to access the overall sector, with the Hong Kong Stock Connect Medical ETF (159137) covering about 70% of the core assets in the innovative drug supply chain [17][19] - The ETF includes leading companies in the medical AI sector and high-end medical devices, effectively covering industry hotspots [18][19]

Group 1: Regulatory Developments - The National Healthcare Security Administration (NHSA) is soliciting public opinions on the "Guidelines for Real-World Comprehensive Value Assessment of Drugs" to establish a unified national evaluation system [1] - Huadong Medicine's subsidiary received FDA approval for clinical trials of DR10624, a novel drug targeting metabolic-associated fatty liver disease [1] - Fosun Pharma's subsidiary has had its drug registration application for erythromycin lactobionate injection accepted by the National Medical Products Administration [2] - Stone Pharmaceutical's new drug for hypertension has received FDA approval for clinical trials in the U.S. [3] - Zhi Mei Ru Kang's siRNA therapy for ALS has entered Phase 2 clinical trials [4] Group 2: Market and Corporate Developments - Cap Bio's major shareholders have increased their stake from 31.52% to 33.05% following capital changes and share buybacks [5] - Bluestar Medical's product is expected to be selected for national centralized procurement of drug-coated balloons, which could enhance its market presence [7] - NVIDIA and Eli Lilly have announced a $1 billion collaboration to establish an AI innovation lab focused on drug discovery and development [8] - Dr. Wang Qiang has transitioned from Xiansheng Pharmaceutical to Ganli Pharmaceutical as Senior Vice President and Chief Strategy Officer [9] Group 3: Quality Control and Safety - China Resources Double Crane has addressed recent quality issues with sodium bicarbonate injection products, clarifying that non-compliance was due to packaging issues during transport [10]

Core Insights - The article highlights the net inflow and outflow of capital in the Hong Kong stock market, with Kuaishou-W, Tencent Holdings, and Southern Hang Seng Technology leading in net inflows, while China Mobile, Meituan-W, and the Tracker Fund of Hong Kong experienced the highest net outflows [1][2]. Group 1: Net Inflows - Kuaishou-W (01024) recorded a net inflow of 2.25 billion, representing a 33.62% increase in its closing price to 80.250, up by 7.43% [2]. - Tencent Holdings (00700) saw a net inflow of 2.00 billion, with a net inflow ratio of 11.73%, closing at 623.000, an increase of 1.96% [2]. - Southern Hang Seng Technology (03033) had a net inflow of 857 million, with a net inflow ratio of 12.00%, closing at 5.740, up by 3.14% [2]. Group 2: Net Outflows - China Mobile (00941) experienced the highest net outflow of -1.03 billion, with a net outflow ratio of -40.96%, closing at 81.150, up by 0.25% [2]. - Meituan-W (03690) had a net outflow of -488 million, with a net outflow ratio of -4.32%, closing at 105.000, an increase of 6.60% [2]. - The Tracker Fund of Hong Kong (02800) saw a net outflow of -425 million, with a net outflow ratio of -4.65%, closing at 26.800, up by 1.52% [2]. Group 3: Net Inflow Ratios - Qinhuangdao Port Co., Ltd. (03369) led with a net inflow ratio of 76.18%, with a net inflow of 1.0376 million, closing at 2.680, up by 0.37% [3]. - China Water Affairs Group (00855) followed with a net inflow ratio of 58.76%, net inflow of 16.8665 million, closing at 5.660, up by 2.35% [3]. - Uni-President China Holdings Ltd. (00220) had a net inflow ratio of 51.73%, with a net inflow of 45.0968 million, closing at 8.450, up by 5.23% [3]. Group 4: Net Outflow Ratios - Country Garden Services Holdings Company Limited (06098) had the highest net outflow ratio of -61.71%, with a net outflow of -29.9428 million, closing at 6.250, down by 0.48% [3]. - Zhiyuan Holdings Limited (00990) followed with a net outflow ratio of -60.45%, net outflow of -21.7419 million, closing at 0.730, up by 4.29% [3]. - Hong Kong Travel (00308) experienced a net outflow ratio of -55.01%, with a net outflow of -17.0295 million, closing at 1.360, unchanged [3].

医药生物行业 行业研究 | 深度报告 减脂保肌强协同，小核酸开启减重新纪元 —医药行业专题报告 核心观点 投资建议与投资标的 ⚫ 小核酸药物在减重领域浮现出 INHBE 和 ALK7 等潜力靶点。对比 GLP-1，小核酸药 物将引领减重从单纯地"抑制食欲"推向"精准调控脂代谢"，并可实现长效减 重，有望开启更优质、更健康的减重新纪元。海外龙头公司管线处于临床早期，而 国内公司已快速布局小核酸减重管线，在靶点、递送平台和适应症三方面奋起直 追，有望加速释放小核酸在健康减重及脂肪性肝病等领域的潜在价值。相关标的： 恒瑞医药(600276，买入)、信达生物(01801，未评级)、石药集团(01093，未评 级)、信立泰(002294，增持)、中国生物制药(01177，未评级)、阳光诺和(688621， 买入)；以及其他小核酸标的：悦康药业(688658，买入)、前沿生物-U(688221，未 评级)、福元医药(601089，未评级)、成都先导(688222，未评级)、热景生物 (688068，未评级)、必贝特-U(688759，未评级)、瑞博生物(06938，未评级)。 风险提示 1. 如果小核酸药物后续减重临床数 ...

Group 1 - The pharmaceutical industry in A-shares is showing a recovery trend, with some companies exceeding performance expectations for 2025 [1][14] - WuXi AppTec expects revenue of approximately 45.456 billion yuan for 2025, a year-on-year increase of about 15.84%, and a net profit of approximately 19.151 billion yuan, a year-on-year increase of about 102.65% [1][15] - WuXi AppTec's performance is driven by stable growth in its main business and the sale of equity in three companies, generating nearly 5.6 billion yuan in revenue [1][15] Group 2 - WoHua Pharmaceutical anticipates a net profit between 80 million and 115 million yuan for 2025, representing a year-on-year increase of 119.76% to 215.90% [2][16] - The growth in WoHua's performance is attributed to the price-volume trade-off trend after the entry of its product into centralized procurement and the extension to outpatient markets [3][17] Group 3 - Kangchen Pharmaceutical expects a net profit between 14.5 million and 17.5 million yuan for 2025, a year-on-year increase of 243% to 315% [4][19] - The company attributes its performance to the absence of goodwill impairment provisions for 2025, following a decline in revenue from a previously acquired business [5][19] Group 4 - Baiaosaitu is projected to achieve a net profit growth of 249.5% in 2025, with expected revenue of 1.31 billion yuan, a year-on-year increase of 37.75% [6][20] - The company began to achieve commercial profitability in 2024, successfully turning around its financial performance [6][20] Group 5 - The Chinese pharmaceutical market is expected to see significant developments in 2026, with a focus on innovative drug research and business development (BD) [7][21] - China has become the second-largest market for innovative drug launches globally, with leading pharmaceutical companies showing R&D intensities close to global averages [7][21] Group 6 - The total value of innovative drug licensing transactions from China is expected to exceed 130 billion USD in 2025, indicating strong recognition of Chinese pipelines by overseas buyers [9][23] - The CXO service industry is recovering, with predictions that the market size will approach 100 billion USD in 2026, driven by increased demand from innovative drug development [9][23] Group 7 - The AI pharmaceutical sector is becoming increasingly active, with significant transactions and the listing of AI companies on stock exchanges [11][25] - The global market for AI solutions in healthcare is projected to grow from 13.7 billion USD in 2022 to 155.3 billion USD by 2030, highlighting the potential for companies in this space [13][27]

Market Overview - The Hang Seng Index reached a high of 27,143 points, close to the November high of 27,188 points, but the upward momentum has slowed down [1] - The trading volume in the Hong Kong market was robust, exceeding 276 billion, indicating high market activity [1] - The A-share market also saw increased trading volume, approaching 3.6 trillion, reflecting a similar trend in market enthusiasm [1] Investor Sentiment - After the Hang Seng Index surpassed 27,100 points, some investors became more conservative, opting to lock in profits by selling call warrants and buying put warrants [2] - The market is expected to experience a short-term adjustment around the 27,000-point level, as investors digest the recent rapid gains of nearly 1,000 points in about a week [2] Individual Stocks - Zijin Mining (02899) has shown strong performance, reaching a high of 40.7 HKD, with positive sentiment towards precious metals expected to continue [3] - The international gold price is projected to rise to 5,000 USD per ounce, with current prices around 4,600 USD, indicating a bullish outlook for precious metals [3] - Investors are encouraged to consider leveraged products related to precious metals, such as call warrants for Zijin Mining with a strike price of 48.65 HKD [4] Other Stocks of Interest - Jiangxi Copper (00358) is gaining attention, with a notable increase in street stock volume, indicating growing investor interest [5] - The company derives 20%-30% of its profits from gold, making it a dual-play opportunity for investors [5] - Stone Pharmaceutical (01093) has reached a high of 10 HKD, with potential for further gains as AI applications in pharmaceuticals are expected to enhance profitability [6] - WuXi Biologics (2269) is also benefiting from AI in drug development, with its stock price nearing 40.2 HKD, close to its previous high of 42.6 HKD [7] Insurance Sector - China Life Insurance (02638) has shown impressive performance, nearly doubling in value over the past year, with a current high of 33.18 HKD [8] - The insurance sector is expected to benefit from improved fundamentals and increased market activity, with long-term capital inflows supporting growth [8] - Investors are advised to consider call warrants for China Life with a strike price of 35.02 HKD, which may soon reach the strike price [8]

Core Viewpoint - The stock of CSPC Pharmaceutical Group (01093) has shown significant movement, with a 53% increase in related warrants, indicating strong market interest and potential for further price challenges in the near future [1][7]. Company Analysis - CSPC Pharmaceutical's latest stock price is 9.96 HKD, with a slight increase of 1.53% and a trading volume of 6.79 billion HKD. The current support levels are at 8.90 HKD and 8.18 HKD, while resistance levels are at 10.32 HKD and 11.00 HKD, suggesting a 51% probability of upward movement [1]. - The technical indicators for CSPC show an RSI of 76, indicating an overbought condition, and both the Williams and stochastic indicators are signaling a sell [2]. - The stock has rebounded to 10 HKD after a previous high of 11.49 HKD in August-September of the previous year, suggesting potential for future price challenges [4]. Industry Insights - The application of AI in the biopharmaceutical sector is highlighted as a key driver for innovation and profitability, with CSPC and similar companies benefiting from this trend [4]. - The biopharmaceutical sector, including companies like WuXi Biologics (2269), is experiencing high market expectations for profitability, with stock prices reflecting this optimism [5][6]. - The overall sentiment in the biopharmaceutical sector is strong, but technical indicators suggest that many stocks, including CSPC, are facing overbought conditions, indicating a potential for price corrections [6][7]. Warrants and Leverage - The warrants related to CSPC have shown significant leverage effects, with some warrants increasing by as much as 53% in response to the stock's movements. The warrants' performance indicates a strong correlation with the underlying stock [7][9]. - Specific warrants, such as the HSBC call warrant (17233), have a leverage of 7.5 times and are positioned close to the current stock price, enhancing their potential for value appreciation [9][10]. - The recommended warrants for cautious investors include the HSBC call warrant (17233) and the Bank of China bull warrant (65938), both of which offer favorable leverage and lower premium levels [9][11].